Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed MM patients Approval based on positive results from ...

Subject to shareholder approval at the subsequent Annual General Meeting (AGM), the Board of Directors of Sanofi Consumer ...

This adjustment represents a significant 40.39% increase in share count, a 0.34% impact on the current portfolio, with a total value of ?4,833,700. The second largest increase was Tecnoglass Inc (NYSE ...

Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the ...

Sanofi India Ltd., incorporated in the year 1956, is a Mid Cap company (having a market cap of Rs 11,687.23 Crore) operating in Pharmaceuticals sector. Sanofi India Ltd. key Products/Revenue Segments ...

The Japanese Ministry of Health, Labor and Welfare (MHLW) in Japan has approved Sarclisa (isatuximab), in combination with ...

Sarclisa approved in Japan for patients with newly diagnosed multiple myeloma Approval offers access to new treatment options for newly diagnosed ...

Ms. Lawver, former Chief Commercial Officer of Dexcom and Global Vice President at Johnson & Johnson responsible for billion-dollar ...

A look ahead at exciting HS updates to be presented at AAD, including emerging therapies, new clinical insights, and procedural advancements.

Pfizer Inc. has announced that Patrizia Cavazzoni, M.D. will rejoin the company as Chief Medical Officer, Executive Vice ...

US drugmaker Eli Lilly has launched 7.5mg and 10mg Zepbound (tirzepatide) single-dose vials for the treatment of obesity.

Mutations in BRCA1 do not appear to contribute significantly to the risk of prostate cancer progression, according to DNA ...